Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Completed · Phase 3 · NCT03473223
Conditions: Acute Coronary Syndrome
At a glance
- Research payments reported, 2025
- $429,636
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 18,226
About the trial
- Sponsor
- CSL Behring
- Tested
- Apolipoprotein A-I [human] (apoA-I) (biological), Placebo (other)
- Dates
- Started 2018-03-21; completion 2023-11-17
- Results posted
- Yes
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.
From ClinicalTrials.gov, last updated 2025-01-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $429,636 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ryan Y. Tsuda, MD Interventional Cardiology · Tucson, AZ
- Bruce M. Graham, MD Interventional Cardiology · Muncie, IN
- Charles M. Gibson, M.D. Interventional Cardiology · Boston, MA
- Joseph F. Mcgarvey JR., M.D. Interventional Cardiology · Bethlehem, PA
- Brian H. Negus, MD Interventional Cardiology · Chattanooga, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Beth Israel Deaconess Medical Center, MA $419,152
- Chi Institute for Research and Innovation $8,000
- Doylestown Hospital $1,300
- Indiana University Health, IN $1,109
- Biomedical Research and Education Foundation of Southern Arizona $75
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.